Tag: EUR

VILVI Group, kurią sudaro AB „Vilkyškių pieninė“, AB „Modest“, AB „Kelmės pieninė“, UAB „Kelmės pienas“, AB „Pieno logistika“ ir SIA „Baltic Dairy Board“, 2025 m. birželio mėnesį konsoliduotos pardavimų pajamos buvo 24.40 mln. Eur arba 13.3% didesnės negu 2024 m. birželio mėnesį. Konsoliduoti Grupės pardavimai 2025 m. sausio - birželio mėn. buvo 142.85 mln. EUR arba 22.1% didesni negu per tą patį laikotarpį 2024 m.

VILVI Group, which consists of Vilkyškių pieninė AB, Modest AB, Kelmės pieninė AB, Kelmės pienas UAB, Pieno logistika AB and Baltic Dairy Board SIA, consolidated sales for June 2025 amounted EUR 24.40 million – 13.3% increase comparing to June 2024. The consolidated sales of the Group for period January – June 2025 amounted to 142.85 million EUR 22.1% increase comparing to the same period last year.

ORION CORPORATION
STOCK EXCHANGE RELEASE – INSIDE INFORMATION
9 JULY 2025 at 13.00 EEST
        

Hepsor AS, registry code 12099216 (the Company) Supervisory Board adopted a decision on 8 July 2025 to increase the share capital of the company by EUR 57,821. The increase of the share capital is linked to the acquisition of a 20% stake in Hepsor Latvia OÜ (registry code 16193797) from Hugomon OÜ (registry code 14221704), approved by a shareholders' resolution of 12 June 2025, for which the company will pay in part by issuing shares in the company to Hugomon OÜ.

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 8, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.

Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 8 juillet 2025 – GENFIT (Nasdaq et Euronext: GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui le bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial.

8 July 2025 - Reference is made to the stock exchange announcement made by Prosafe SE (the "Company") on 16 May 2025 regarding the extraordinary general meeting's resolution to decrease the share capital of the Company by EUR 22,157,127.24, from EUR 22,335,813.75 to EUR 178,686.51, through a decrease of the nominal value of each share in the Company by EUR 1.24, from EUR 1.25 to EUR 0.01.

On 5 February 2025, Pandora announced a new share buyback programme, cf. Company announcement no. 923. The share buyback programme is executed in accordance with Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation).
                                                                                                                                                      
The purpose of the programme is to reduce Pandora’s share capital and to meet obligations arising from company incentive programmes.

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT